



FINANCIAL TEAR SHEET

Corporate Profile


Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce’s technology also looks to match and deliver the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as the knowledge acquired from Jounce’s Translational Science Platform, to create a sustainable pipeline that makes a difference in the lives of cancer patients.

Stock Information

JNCE (COMMON STOCK)

Exchange	NASDAQ GS (US Dollar)
Price	\$21.72
Change (%)	▼ 1.38 (5.97%)
Volume	312,815
52 Week Low	\$11.05
Market Cap	\$700,377,951
Rolling EPS	-0.17
PE Ratio	0
Shares Outstanding	32,245,762

Data as of 02/23/18 4:00 p.m. ET



Recent Headlines & Events

01/03/18 - 8:00 a.m.

Jounce Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

12/14/17 - 7:00 a.m.

Jounce Therapeutics Added to NASDAQ Biotechnology Index

12/07/17 - 8:01 a.m.

Jounce Therapeutics to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

There are currently no events scheduled.

SEC Filings

FILING DATE	FORM
02/14/18	SC 13G/A
02/13/18	SC 13G
02/08/18	SC 13G
02/05/18	4

Data provided by NASDAQ. Stock information is delayed a minimum of 15 minutes.